Positioning no disclosures inside 60 days, left as found
Options put/call open interest 3.67, read 2026-10-24
Ethical does not pass the values gate
Price28.06 USD
Fair value24.39
Ethical score70.0/100
Our investment reviews on this name
2026-10-11Read Accumulation27.49+2.1% to today ✓Markdown gives way to Accumulation with volume flow in agreement
2026-10-02Read Markdown27.08+3.6% to today Markup gives way to Markdown
2026-08-28Read Markup28.47-1.4% to today Distribution gives way to Markup after a 24% rise in 8 weeks
2026-07-02Read Distribution22.94+22.3% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Edgewell Personal Care Company holds its Markup at $28.06. The statistical read favours the sellers, held for 49 days.
As held on the ledger · 2026-10-23
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 49 days
Price at the screen
$28.06
Valuation
N/A trailing · 14.52 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.35
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
37.61%
Below 33%
Interest-bearing debt is 37.6% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
9.68%
Below 49%
Money owed to the company is 9.7% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Edgewell Personal Care's business is in a permissible area, but its interest-bearing debt is about 38% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when EPC's ethical verdict changes
Today EPC does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. The price runs 15.6% above the base estimate.
Third-party analyst targets: 6 covering, consensus Buy. The average target sits +9% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Daily shaves and lotions hide weak returns
Think of the bathroom cabinet that gets restocked every few months with razors, sun cream and feminine care items. Edgewell makes those staples yet posts revenue growth of just 1 percent, a negative profit margin and negative return on equity. The shares sit above our fair value estimate with no margin of safety, so we pass.
Forward earnings trade at 14.5 times while the business shows no pricing power or scale advantage. Analyst targets cluster around current levels but offer no cushion against the thin results already on show. Ethical checks clear, yet the numbers do not.
Defensive labels can mask cyclical volume pressure and brand erosion in a crowded aisle. Without a visible moat or path back to positive returns, the valuation leaves little room for error. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
EPC trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-25Accumulation$28.89+1.3%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 25% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (6 analysts) rates it none, with a mean price target of $24.
2026-10-18Accumulation$28.53+3.8%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (6 analysts) rates it none, with a mean price target of $24.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (6 analysts) rates it none, with a mean price target of $24.
2026-10-02Markdown · changed$27.08-4.9%Entry 6
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (6 analysts) rates it none, with a mean price target of $24.
2026-08-28Markup · changed$28.47-4.0%Entry 5
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 4.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (6 analysts) rates it none, with a mean price target of $24.
2026-07-27Distribution$29.66+29.3%Entry 4
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 29.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (6 analysts) rates it none, with a mean price target of $24.
2026-07-18Distribution$22.94+0.0%Entry 3
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (6 analysts) rates it none, with a mean price target of $24.
2026-07-03Distribution$22.94+0.0%Entry 2
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$22.94Entry 1
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
